

# tissue genesis inc.

## NEWS RELEASE

### Media contact:

Tom Cannon  
Tissue Genesis, Inc.  
808-772-5560  
tcannon@tissuegenesis.com


For Immediate Release

July 8, 2011

### **Tissue Genesis Joins with NASA & DoD for the Last Space Shuttle Launch, STS-135**

HONOLULU, HAWAII – With the launch of the last space shuttle, Atlantis, Tissue Genesis announced that they are continuing to explore scientific possibilities in space by sending adult stem cells into microgravity to further research efforts.

Tissue Genesis has provided science experiments, hardware/payload integration, and adult stem cells in support of a NASA/DoD research collaboration to find ways to



*TGI Cell Isolation System in the NASA lab*

combat the negative effects of space travel on living systems. The breakdown of muscle, bone and other body systems is similar to events that occur when tissue is injured or diseased. Tissue Genesis will be testing the

effectiveness of adult stem cells recovered from the Tissue Genesis® Cell Isolation System™ to negate the breakdown cascade. Cell Isolation System recovered adult stems cells are known to produce growth factors and other proteins that may important for tissue repair. These experiments were made possible due to the collaboration of many teams including the Pacific Telehealth and Technology Hui, Telemedicine and Advanced Research Projects Center, NASA Ames Research Center, and US Army Medical Research and Material Command.



*Tens of millions of adult stem and regenerative cells recovered by the Tissue Genesis Cell Isolation System*

Tissue Genesis' biologists and engineers prepared these experiments and hardware in its Kaka`ako lab before shipment to the Kennedy Space Center. The STS-135 launch of the space shuttle Atlantis will culminate months of planning and on-the-ground testing making ready to join an elite series of cell culture experiments carried out on the space shuttle system.



“We are honored to be a part of the last space shuttle program by integrating our scientific research and development, involving adult stem cells, to experiments that can be tested in space,” states Anton C. Krucky, President and CEO of Tissue Genesis. “This is truly a historic moment and is an accumulation of many years of hard work and ingenuity. With the leadership of Tissue Genesis’ Tom Cannon and Cris Kosnik, we are confident in mission success and are so proud of this team and what we have accomplished today.”

Shown left to right are Dr. Joon Paek, Anthony Yang, and Shannon Iwami. Local alumnus, Ms. Iwami is a graduate of Baldwin High School and the University of Hawaii at Mānoa, and Mr. Yang is a graduate of Punahou High School.

This last space shuttle experiment is significant because it caps a history 19 missions that our scientists have had with the shuttle in what is referred to as the Cell Culture

Module. This module is an automated perfusion system which allows for a variety of automated experiment manipulations and provides a controlled, physiologic growth environment. Although automated, the module does require minimal crew interaction approximately three hours after launch and eight hours prior to landing. This final space shuttle flight will have Mission Specialists Sandy Magnus and Rex Walheim supervising the Cell Culture Module and the onboard experiments.

**About Tissue Genesis, Inc.**

An emerging leader in adipose-derived cell therapy and regenerative medicine, Tissue Genesis, Inc. is a high-growth, clinical-stage company based in Honolulu, Hawai'i. Industry leading physicians, engineers and scientists have developed a proprietary therapy for Tissue Genesis that may deliver innovative medical solutions for a wide range of existing medical problems, including: cardiac and peripheral vascular disease; orthopedic injuries; cosmetic and soft tissue defects; and many other applications. For more information, visit [www.tissuegenesis.com](http://www.tissuegenesis.com).

**Safe Harbor Statement**

This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of Tissue Genesis, Inc., and members of its management as well as the assumptions on which such statements are based. There can be no assurance that Tissue Genesis will be able to commercially develop its therapeutic cell technology or products, that necessary regulatory approval will be obtained, that any clinical trials will be successful, or that the proposed treatments will prove to be safe and/or effective. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events, or changes to future operating results.

###